BBIO Q3 2019 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M

Gross Profit

$24M90.7% margin

Operating Income

-$55M-203.9% margin

Net Income

-$60M-224.3% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$641M

Total Liabilities

$116M

Stockholders' Equity

$460M

Cash & Equivalents

$414M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$0	—
Gross Profit	$24M	$0	—
Operating Income	-$55M	-$41M	-31.5%
Net Income	-$60M	-$31M	-91.0%